Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Wolf-Otto Bechstein
Based on 4 articles published since 2010
(Why 4 articles?)
||||

Between 2010 and 2020, W-O Bechstein wrote the following 4 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Clinical Trial CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. 2017

Sinn, Marianne / Bahra, Marcus / Liersch, Torsten / Gellert, Klaus / Messmann, Helmut / Bechstein, Wolf / Waldschmidt, Dirk / Jacobasch, Lutz / Wilhelm, Martin / Rau, Bettina M / Grützmann, Robert / Weinmann, Arndt / Maschmeyer, Georg / Pelzer, Uwe / Stieler, Jens M / Striefler, Jana K / Ghadimi, Michael / Bischoff, Sven / Dörken, Bernd / Oettle, Helmut / Riess, Hanno. ·Marianne Sinn, Marcus Bahra, Uwe Pelzer, Jens M. Stieler, Jana K. Striefler, Sven Bischoff, Bernd Dörken, and Hanno Riess, Charité-Universitätsmedizin Berlin · Klaus Gellert, Sana Klinikum Lichtenberg, Berlin · Torsten Liersch and Michael Ghadimi, Universitätsmedizin Göttingen, Göttingen · Helmut Messmann, Klinikum Augsburg, Augsburg · Wolf Bechstein, Universitätsklinikum Frankfurt, Frankfurt · Dirk Waldschmidt, Universitätsklinikum Köln, Köln · Lutz Jacobasch, Clinical Center, Dresden · Martin Wilhelm, Paracelsus Medical University, Nürnberg · Bettina M. Rau, Universitätsmedizin Rostock, and Municipal Hospital of Neumarkt, Rostock · Robert Grützmann, Universitätsklinikum Carl Gustav Carus, Dresden, and Universitätsklinikum Erlangen, Erlangen · Arndt Weinmann, Klinikum der Johannes Gutenberg-Universität, Mainz · Georg Maschmeyer, Ernst von Bergmann Klinikum, Potsdam · and Helmut Oettle, Clinical Center, Friedrichshafen, Germany. ·J Clin Oncol · Pubmed #28817370.

ABSTRACT: Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has shown efficacy in the treatment of advanced PDAC and was considered to improve survival in patients with primarily resectable PDAC after R0 resection. Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to one of two study arms: gemcitabine 1,000 mg/m

2 Clinical Trial Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. 2015

Golcher, Henriette / Brunner, Thomas B / Witzigmann, Helmut / Marti, Lukas / Bechstein, Wolf-Otto / Bruns, Christiane / Jungnickel, Henry / Schreiber, Stefan / Grabenbauer, Gerhard G / Meyer, Thomas / Merkel, Susanne / Fietkau, Rainer / Hohenberger, Werner. ·Department of Surgery, University Hospital Erlangen, Krankenhausstr. 12, 91054, Erlangen, Germany, henriette.golcher@uk-erlangen.de. ·Strahlenther Onkol · Pubmed #25252602.

ABSTRACT: BACKGROUND: In nonrandomized trials, neoadjuvant treatment was reported to prolong survival in patients with pancreatic cancer. As neoadjuvant chemoradiation is established for the treatment of rectal cancer we examined the value of neoadjuvant chemoradiotherapy in pancreatic cancer in a randomized phase II trial. Radiological staging defining resectability was basic information prior to randomization in contrast to adjuvant therapy trials resting on pathological staging. PATIENTS AND METHODS: Patients with resectable adenocarcinoma of the pancreatic head were randomized to primary surgery (Arm A) or neoadjuvant chemoradiotherapy followed by surgery (Arm B), which was followed by adjuvant chemotherapy in both arms. A total of 254 patients were required to detect a 4.33-month improvement in median overall survival (mOS). RESULTS: The trial was stopped after 73 patients; 66 patients were eligible for analysis. Twenty nine of 33 allocated patients received chemoradiotherapy. Radiotherapy was completed in all patients. Chemotherapy was changed in 3 patients due to toxicity. Tumor resection was performed in 23 vs. 19 patients (A vs. B). The R0 resection rate was 48% (A) and 52% (B, P = 0.81) and (y)pN0 was 30% (A) vs. 39% (B, P = 0.44), respectively. Postoperative complications were comparable in both groups. mOS was 14.4 vs. 17.4 months (A vs. B; intention-to-treat analysis; P = 0.96). After tumor resection, mOS was 18.9 vs. 25.0 months (A vs. B; P = 0.79). CONCLUSION: This worldwide first randomized trial for neoadjuvant chemoradiotherapy in pancreatic cancer showed that neoadjuvant chemoradiation is safe with respect to toxicity, perioperative morbidity, and mortality. Nevertheless, the trial was terminated early due to slow recruiting and the results were not significant. ISRCTN78805636; NCT00335543.

3 Clinical Trial Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. 2012

Löhr, J M / Haas, S L / Bechstein, W-O / Bodoky, G / Cwiertka, K / Fischbach, W / Fölsch, U R / Jäger, D / Osinsky, D / Prausova, J / Schmidt, W E / Lutz, M P / Anonymous1191075. ·Department of Medicine II, University Hospital Mannheim, Mannheim, Germany. matthias.lohr@ki.se ·Ann Oncol · Pubmed #21896540.

ABSTRACT: BACKGROUND: Paclitaxel embedded in cationic liposomes (EndoTAG™-1; ET) is an innovative agent targeting tumor endothelial cells. This randomized controlled phase II trial evaluated the safety and efficacy of ET in combination with gemcitabine (GEM) in advanced pancreatic cancer (PDAC). PATIENTS AND METHODS: Chemotherapy-naive patients with locally advanced or metastatic disease were randomly assigned to receive weekly GEM 1000 mg/m(2) or GEM plus twice-weekly ET 11, 22 or 44 mg/m(2) for 7 weeks. After a safety run-in of 100 patients, a second cohort continued treatment. End points included overall survival (OS), progression-free survival (PFS), tumor response and safety. RESULTS: Two hundred and twelve patients were randomly allocated to the study and 200 were treated (80% metastatic, 20% locally advanced). Adverse events were manageable and reversible. Transient thrombocytopenia and infusion reactions with chills and pyrexia mostly grade 1 or 2 occurred in the ET groups. Disease control rate after the first treatment cycle was 43% with GEM and 60%, 65% and 52% in the GEM + ET cohorts. Median PFS reached 2.7 compared with 4.1, 4.6 and 4.4 months, respectively. Median OS was 6.8 compared with 8.1, 8.7 and 9.3 months, respectively. CONCLUSIONS: Treatment of advanced PDAC with GEM + ET was generally well tolerated. GEM + ET showed beneficial survival and efficacy. A randomized phase III trial should confirm this positive trend.

4 Article Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. 2019

Wittel, U A / Lubgan, D / Ghadimi, M / Belyaev, O / Uhl, W / Bechstein, W O / Grützmann, R / Hohenberger, W M / Schmid, A / Jacobasch, L / Croner, R S / Reinacher-Schick, A / Hopt, U T / Pirkl, A / Oettle, H / Fietkau, R / Golcher, H. ·Department for General- und Visceral Surgery, Medical Center and Faculty of Medicine University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany. uwe.wittel@unikklinik-freiburg.de. · Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. · Department of General, Visceral and Pediatric Surgery, Medical Center Georg-August-University Göttingen, Göttingen, Germany. · Department of Surgery, St. Josef Hospital Ruhr-University Bochum, Bochum, Germany. · Department of General and Visceral Surgery, Frankfurt University Hospital and Clinics, Frankfurt, Germany. · Department of Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. · Department of Radiology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. · Private Practice, Hematology/Oncology, Dresden, Germany. · Department of Surgery, University Hospital Magdeburg, Magdeburg, Germany. · Department for Hematology, Oncology and Palliative Care, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. · Department for General- und Visceral Surgery, Medical Center and Faculty of Medicine University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany. · Medical Centre for Information and Communication Technology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. · Outpatient Department Hematology/Oncology, Friedrichshafen, Germany. ·BMC Cancer · Pubmed #31640628.

ABSTRACT: BACKGROUND: One critical step in the therapy of patients with localized pancreatic cancer is the determination of local resectability. The decision between primary surgery versus upfront local or systemic cancer therapy seems especially to differ between pancreatic cancer centers. In our cohort study, we analyzed the independent judgement of resectability of five experienced high volume pancreatic surgeons in 200 consecutive patients with borderline resectable or locally advanced pancreatic cancer. METHODS: Pretherapeutic CT or MRI scans of 200 consecutive patients with borderline resectable or locally advanced pancreatic cancer were evaluated by 5 independent pancreatic surgeons. Resectability and the degree of abutment of the tumor to the venous and arterial structures adjacent to the pancreas were reported. Interrater reliability and dispersion indices were compared. RESULTS: One hundred ninety-four CT scans and 6 MRI scans were evaluated and all parameters were evaluated by all surgeons in 133 (66.5%) cases. Low agreement was observed for tumor infiltration of venous structures (κ = 0.265 and κ = 0.285) while good agreement was achieved for the abutment of the tumor to arterial structures (interrater reliability celiac trunk κ = 0.708 P < 0.001). In patients with vascular tumor contact indicating locally advanced disease, surgeons highly agreed on unresectability, but in patients with vascular tumor abutment consistent with borderline resectable disease, the judgement of resectability was less uniform (dispersion index locally advanced vs. borderline resectable p < 0.05). CONCLUSION: Excellent agreement between surgeons exists in determining the presence of arterial abutment and locally advanced pancreatic cancer. The determination of resectability in borderline resectable patients is influenced by additional subjective factors. TRIAL REGISTRATION: EudraCT:2009-014476-21 (2013-02-22) and NCT01827553 (2013-04-09).